UPDATE: MLV & Co. Initiates Coverage On Sorrento Therapeutics On Good Cynviloq Potential
In a report published Thursday, MLV & Co. analyst Arlinda Lee initiated coverage on Sorrento Therapeutics (NASDAQ: SRNE) with a Buy rating and $9.00 price target.
In the report, MLV & Co. noted, “We are initiating coverage of SRNE with a Buy rating and $9 price target. We believe that lead product candidate Cynviloq, a next generation paclitaxel, has a 75% chance of showing bioequivalence to CELG's Abraxane (CELG – $-159.94 - not covered), gaining FDA approval, and capturing 25% of the addressable paclitaxel market. Second product candidate resiniferatoxin (RTX), a non-opioid severe pain drug, also contributes to our probability-adjusted valuation.”
Sorrento Therapeutics closed on Wednesday at $5.62.
Latest Ratings for SRNE
Date | Firm | Action | From | To |
---|---|---|---|---|
Aug 2021 | HC Wainwright & Co. | Maintains | Buy | |
Jan 2021 | Alliance Global Partners | Initiates Coverage On | Buy | |
Jul 2020 | HC Wainwright & Co. | Maintains | Buy |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Arlinda Lee MLV & Co.Analyst Color Initiation Analyst Ratings